Program

99
92
5
3
2
1
1

Journal Year Published

10
16
11
20
10
8
9
10
12
12
10
12
4

Author

144
183
175
135
127
119
118
115
108
94
87
81
77
57
52
50
45
44
42
34

Category

75
47
31
25
6
5
2
2
2
1
1

Keyword

58
43
32
19
18
16
15
15
14
13
13
12
12
12
11
11
10
10
10
9

Journal

16
13
12
5
4
4
4
3
3
3
3
3
3
3
2
2
2
2
2
2

NCATS Publications

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.


Lin GL, et al.


Sci Transl Med , (11), 2019.

Article Pubmed

Sample image from publication page

eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma.


Chan K, Robert F, Oertlin C, Kapeller-Libermann D, Avizonis D, Gutierrez J, Handly-Santana A, Doubrovin M, Park J, Schoepfer C, Da Silva B, Yao M, Gorton F, Shi J, Thomas C, Brown LE, Porco JA, Pollak M, Larsson O, Pelletier J, Chio IIC


Nat Commun , (10), 5151, 2019.

Article Pubmed

Sample image from publication page

Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.


Kaur S, Schwartz AL, Jordan DG, Soto-Pantoja DR, Kuo B, Elkahloun AG, Mathews Griner L, Thomas C, Ferrer-Alegre M, Thomas A, Tang SW, Rajapakse VN, Pommier Y, Roberts DD


Front Oncol , (9), 994, 2019.

Article Pubmed

Sample image from publication page

Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets.


Vootukuri S, Li J, Nedelman M, Thomas C, Jiang J, Babayeva M, Coller BS


J Clin Transl Sci , (3), 65-74, 2019.

Article Pubmed

Sample image from publication page

Targeting of Fumarate Hydratase from Mycobacterium tuberculosis Using Allosteric Inhibitors with a Dimeric-Binding Mode.


Whitehouse AJ, Libardo MDJ, Kasbekar M, Brear PD, Fischer G, Thomas C, Barry CE, Boshoff HIM, Coyne AG, Abell C


J. Med. Chem. , 2019.

Article Pubmed

Sample image from publication page

High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis.


Alkhilaiwi F, Paul S, Zhou D, Zhang X, Wang F, Palechor-Ceron N, Wilson K, Guha R, Ferrer-Alegre M, Grant N, Thomas C, Schlegel R, Yuan H


Papillomavirus Res , (8), 100181, 2019.

Article Pubmed

Sample image from publication page

Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell-Like Phenotype.


Bian Y, Teper Y, Mathews Griner LA, Aiken TJ, Shukla V, Guha R, Shinn P, Xin HW, Pflicke H, Powers AS, Li D, Jiang J, Patel P, Rogers SA, Aubé J, Ferrer-Alegre M, Thomas C, Rudloff U


Mol. Cancer Ther. , (18), 2097-2110, 2019.

Article Pubmed

Sample image from publication page

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.


Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris P, Stewart BW, Thomas C, Thompson SM, Moaddel R, Gould TD


Br. J. Pharmacol. , (176), 2573-2592, 2019.

Article Pubmed

Sample image from publication page

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.


Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris P, Thomas C, Moaddel R, Zarate CA, Gould TD


Proc. Natl. Acad. Sci. U.S.A. , (116), 6441-6450, 2019.

Article Pubmed

Sample image from publication page

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.


Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris P, Thomas C, Zarate CA, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD


Proc. Natl. Acad. Sci. U.S.A. , (116), 5160-5169, 2019.

Article Pubmed

Sample image from publication page